50 research outputs found
Federal Policy for Higher Education and the Dilemma of Student Financial Assistance in the 1980\u27s
Statewide Need for and Coordination of Training of Financial Aid Practitioners: The Case of Arizona
Financial Aid, Persistence, and Degree Completion in Masters Degree Programs
This article provides an overview of the research findings from a longitudinal study conducted at a large urban university on student financial aid, persistence, and degree completion of masters degree students. The purpose of the study was to determine how the types and amounts of student financial aid, along with students\u27 demographic and academic characteristics, are related to masters degree completion. Data were analyzed for a large cohort of masters degree students over a four-year period beginning in Fall, 1985 and ending in Summer, 1989
Micro and Mainframe Computer Models for Improved Planning in Awarding Financial Aid to Disadvantaged Students
This article reports the development of two computer models, one mainframe the other microcomputer, which are intended to maximize financial aid awards to disadvantaged students. The models recognize the tendency of students from low-income and minority backgrounds to apply for assistance late in the funding cycle, and permit institutional aid administrators to project the amount of aid needed by such students and to plan for an adequate inventory of funds to accommodate their needs
Spending Patters of College Students who Receive Monetary Awards From a State Scholarship Commission
RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106
Aggressive induction chemotherapy followed by autologous haematopoietic stem cell transplant (auto-HCT) is effective for younger patients with mantle cell lymphoma (MCL). However, the optimal induction regimen is widely debated. The Southwesterm Oncology Group S1106 trial was designed to assess rituximab plushyperCVAD/MTX/ARAC (hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone, alternating with high dose cytarabine and methotrexate) (RH) versus rituximab plus bendamustine (RB) in a randomized phase II trial to select a pre-transplant induction regimen for future development. Patients had previously untreated stage III, IV, or bulky stage II MCL and received either 4 cycles of RH or 6 cycles of RB, followed by auto-HCT. Fifty-three of a planned 160 patients were accrued; an unacceptably high mobilization failure rate (29%) on the RH arm prompted premature study closure. The estimated 2-year progression-free survival (PFS) was 81% vs. 82% and overall survival (OS) was 87% vs. 88% for RB and RH, respectively. RH is not an ideal platform for future multi-centre transplant trials in MCL. RB achieved a 2-year PFS of 81% and a 78% MRD negative rate. Premature closure of the study limited the sample size and the precision of PFS estimates and MRD rates. However, RB can achieve a deep remission and could be a platform for future trials in MCL
RB but not RâHCVAD is a feasible induction regimen prior to autoâHCT in frontline MCL: results of SWOG Study S1106
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/136294/1/bjh14480_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/136294/2/bjh14480.pd